VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA).

New England Biolabs has released the Monarch® Mag Cell-free DNA (cfDNA) Extraction Kit, a bead-based method designed for scalable and reproducible isolation of low abundance cfDNA from plasma, serum, ...

RNA and DNA extraction kits take formalin-fixed tissue samples by storm, enabling superior quality and yields. Researchers using standard extraction protocols that heat samples to eliminate ...

DNA extraction methods are integral to many forms of research, providing clean, isolated genetic material for sequencing. This eBook explores various DNA extraction methods and techniques with key ...

Singleron Introduces PythoN i™, Adding Nuclei Extraction and Tissue Homogenization Functions to its Tissue Processing System Singleron Biotechnologies today announced the launch of PythoN i, an ...

VolitionRx (VNRX) stock jumped 70% in pre-market after achieving 99% pure tumor DNA isolation and detecting 49/49 cancers in a blind study.

Viral diseases pose a significant global health challenge, placing substantial strain on healthcare systems. Accurate identification of viral infections is crucial for monitoring outbreaks, managing ...

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization. HENDERSON, Nev., March 18, ...